Elan: FDA will be under pressure to resume sale of MS drug Tysabri
The way Elan tells it, by the end of this summer the safety panel of the US Food and Drug Administrat ion (FDA) will be under immense pressure to let the sale resume of Tysabri.
The way Elan tells it, by the end of this summer the safety panel of the US Food and Drug Administrat ion (FDA) will be under immense pressure to let the sale resume of Tysabri.
The multiple sclerosis (MS) drug was withdrawn late last February, with dramatic consequences tohopes of sufferers of MS and Crohn's and to the shareholders of Elan and its partner Biogen. Three thousand patients trialled Tysabri in combination with ...
